National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No. 5) (No. PB 39 of 2011) (Cth)
PB 39 of 2011
National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No. 5)
National Health Act 1953
___________________________________________________________________________
I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 27 May 2011
FELICITY MCNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
1 Name of Instrument
(1)This Instrument is the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement Amendment Instrument 2011 (No.5).
(2)This Instrument may also be cited as PB 39 of 2011.
2 Commencement
This Instrument commences on 1 June 2011.
3 Amendments to PB 117 of 2010
Schedule 1 amends the National Health (Chemotherapy Pharmaceuticals Access Program) Special Arrangement 2010 (PB 117 of 2010).
.
Schedule 1 Amendments
Schedule 1, entry for Bleomycin:
substitute:
| Bleomycin | Powder for injection containing bleomycin sulphate 15,000 I.U. (with any determined brand of sodium chloride injection as the required solvent) | Injection | Blenamax | QA | EMP | C1139 C1198 | 10 | 0 |
| Hospira Pty Limited | HH | EMP | C1139 C1198 | 10 | 0 |
Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL for the brand Docetaxel Ebewe with a maximum quantity of 1 and a number of repeats of 0:
omit from the column headed “Circumstances”:
C2439
C3292
Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL for the brand Docetaxel Ebewe with a maximum quantity of 2 and a number of repeats of 0:
(a) omit from the column headed “Circumstances”:
C2439
C3292
(b) omit from the column headed “Purposes”:
P2439
P3292
Schedule 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL for the brand Docetaxel Ebewe:
omit from the column headed “Circumstances”:
C2439
C3292
Schedule 1, entry for Thiotepa:
substitute:
| Thiotepa | Powder for injection 15 mg | Injection/ | Aspen Pharma Pty Ltd | QA | EMP | 2 | 1 |
[6] Schedule 2,
after:
| PL | The Trustee for Virgo Unit Trust (trading as Phebra) | 77 695 661 635 |
insert:
| QA | Aspen Pharma Pty Ltd | 88 004 118 594 |
[7] Schedule 2,
after:
| SH | Schering-Plough Pty Limited | 57 000 235 245 |
omit:
| SI | Sigma Pharmaceuticals (Australia) Pty Ltd | 88 004 118 594 |
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0